Story Poster
Notre Dame Football Recruiting

2025 DE Charlie Woleben Talks Notre Dame Trip

November 6, 2023
2,990

Charlie Woleben‍ made the trip out to Notre Dame a couple weeks ago to see the Irish play Pittsburgh and the 2025 Kansas defensive end left impressed. 

“It was great,” the 6-foot-4, 215-pounder told Irish Sports Daily. “It was a great environment. It was really exciting to be there.

The De Soto High School standout checked in at the indoor facility and ate before connecting with Recruiting Analyst Caleb Davis.

“Then we came back up, listened to the team parents speak for a bit, listened to what they had to say about the recruiting process, and then got to go down back down to the stadium and watched pregame,” Woleben explained. “We watched the victory march, and then watched a great game.”

Woleben enjoyed the Irish’s 58-7 stomping of Pitt.

“It was impressive to watch,” he said. “It was a very exciting game.

“It's always good to see that a team can be dominant. It's also interesting to see how a team performs when the game's on the line, but it's always great to see a team just completely own the game.”

Woleben has early offers from Kansas, Nebraska, Minnesota and Iowa State.

“It's exciting, it's crazy,” he acknowledged. “Being at this point in my life and going from having the opportunity to move on and play more football after high school, it's just a great experience.

“I think the coaches like my speed and length off the edge, my athleticism.”

Davis gave him some insight into how things could proceed with the Irish.

“They want to see more,” Woleben said. “They want to see me in person, come up for a camp maybe this summer.”

Coming back for a camp is something he’s going to consider.

“My biggest thing right now is finding the place that feels right. Somewhere I know I'll be excited to go for five, six years.”

Notre Dame Under Armour Military Appreciation Performance Polo ($74.99 $18.99) 

 
×
subscribe Verify your student status
See Subscription Benefits
Trial only available to users who have never subscribed or participated in a previous trial.